Risk factor
Limited trading liquidity
Profitability factor
Decent dividends
About
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. It also offers contract manufacturing services. In addition, it exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, o
Target Price
The average target price of 4114.TWO is 37 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell